1p19q LOH patterns and expression of p53 and Olig2 in gliomas: Relation with histological types and prognosis

Modern Pathology

Volumn 23, Issue 4, 2010, Pages 619-628

  Durand, Karine S ^a   Guillaudeau, Angélique ^a   Weinbreck, Nicolas ^a   Dearmas, Rafaël ^a   Robert, Sandrine ^a   Chaunavel, Alain ^a   Pommepuy, Isabelle ^a   Bourthoumieu, Sylvie ^a   Caire, François ^a   Sturtz, Franck G ^a   Labrousse, François J ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

1p19q loss of heterozygosity; Glioma; Olig2; P53; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN P53;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CENTROMERE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE MARKER; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TELOMERE;

ADULT; AGED; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; GENE AMPLIFICATION; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950516927     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.185     Document Type: Article

References (46)

1. Dai C, Holland EC. Astrocyte differentiation states and glioma formation. Cancer J 2003;9:72-81.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
3. Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 2004;16:607-613. (Pubitemid 39482982)
4. Arslantas A, Artan S, Oner U, et al. Genomic alterations in low-grade, anaplastic astrocytomas and glio-blastomas. Pathol Oncol Res 2007;13:39-46. (Pubitemid 46883545)
5. Kramar F, Zemanova Z, Michalova K, et al. Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data. J Neurooncol 2007;84:201-211. (Pubitemid 47202130)
6. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-994. (Pubitemid 44521799)
7. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66:9852-9861. (Pubitemid 44672036)
8. Ichimura K, Vogazianou AP, Liu L, et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 2008;27:2097-2108. (Pubitemid 351442746)
9. Bourdon V, Plessis G, Chapon F, et al. Chromosome imbalances in oligodendroglial tumors detected by comparative genomic hybridization. Ann Genet 2004;47:105-111. (Pubitemid 38748492)
10. Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol 2004;70:161-181. (Pubitemid 39545730)
11. Kitange G, Misra A, Law M, et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 2005;42:68-77. (Pubitemid 39582821)
12. Reddy KS. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet 2008;184:77-86.
13. Burger PC, Scheithauer BW. Tumors of the Central Nervous System. American Registry of Pathology: Washington, DC, 2007, pp 596.
14. Barbashina V, Salazar P, Holland EC, et al. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005;11:1119-1128. (Pubitemid 40175761)
15. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-4152. (Pubitemid 29363922)
16. Bello MJ, de Campos JM, Kusak ME, et al. Molecular analysis of genomic abnormalities in human gliomas. Cancer Genet Cytogenet 1994;73:122-129. (Pubitemid 24154005)
17. Boulay JL, Miserez AR, Zweifel C, et al. Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS One 2007;2: e576. (Pubitemid 351260205)
18. Felsberg J, Erkwoh A, Sabel MC, et al. Oligodendro-glial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004;14:121-130. (Pubitemid 38656383)
19. Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008;122:1778-1786. (Pubitemid 351413424)
20. Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005;58:483-487. (Pubitemid 41266639)
21. Ransom DT, Ritland SR, Moertel CA, et al. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer 1992; 5:357-374.
22. Smith JS, Tachibana I, Lee HK, et al. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000;29:16-25. (Pubitemid 30620494)
23. Kros JM, van der Weiden M, Zheng PP, et al. Intratumoral distribution of 1p loss in oligodendroglial tumors. J Neuropathol Exp Neurol 2007;66:1118-1123. (Pubitemid 350294661)
24. Pinto LW, Araujo MB, Vettore AL, et al. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch 2008;452:481-490.
25. Guillaudeau A, Durand K, Pommepuy I, et al. Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. Appl Immunohistochem Mol Morphol 2009;17:220-226.
26. Korshunov A, Sycheva R, Golanov A. Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: the utility of fluorescence in situ hybridization. Clin Cancer Res 2004;10:7820-7826. (Pubitemid 39587519)
27. Marks RA, Zhang S, Montironi R, et al. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate 2008;68:919-923. (Pubitemid 351794156)
28. Okuda K, Sasaki H, Kawano O, et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008.
29. Burger PC, Minn AY, Smith JS, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001;14:842-853.
30. Godfraind C, Rousseau E, Ruchoux MM, et al. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neu-robiol 2003;29:462-471. (Pubitemid 37222720)
31. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendroglio-mas. J Natl Cancer Inst 1998;90:1473-1479. (Pubitemid 28482012)
32. Johnson MD, Vnencak-Jones CL, Toms SA, et al. Allelic losses in oligodendroglial and oligodendroglio-ma-like neoplasms: analysis using microsatellite repeats and polymerase chain reaction. Arch Pathol Lab Med 2003;127:1573-1579.
33. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligo-astrocytoma. J Neuropathol Exp Neurol 1995;54: 91-95.
34. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligoden-droglioma. Arch Pathol Lab Med 2007;131:242-251. (Pubitemid 46255646)
35. Burger PC. What is an oligodendroglioma? Brain Pathol 2002;12:257-259.
36. Daumas-Duport C, Varlet P, Tucker ML, et al. Oligo-dendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 1997;34:37-59. (Pubitemid 27270251)
37. McCarthy BJ, Propp JM, Davis FG, et al. Time trends in oligodendroglial and astrocytic tumor incidence. Neu-roepidemiology 2008;30:34-44.
38. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-1104. (Pubitemid 27430471)
39. Eoli M, Bissola L, Bruzzone MG, et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006;119:84-90.
40. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 2008;67:1-15.
41. Mokhtari K, Paris S, Aguirre-Cruz L, et al. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neuro-biol 2005;31:62-69. (Pubitemid 40222826)
42. Figarella-Branger D, Colin C, Coulibaly B, et al. [Histological and molecular classification of gliomas]. Rev Neurol (Paris) 2008;164:505-515.
43. Kraus A, Neff F, Behn M, et al. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblasto-ma cells. Int J Cancer 1999;80:930-934. (Pubitemid 29108870)
44. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008;68:2551-2556. (Pubitemid 351556249)
45. Ermoian RP, Kaprealian T, Lamborn KR, et al. Signal transduction molecules in gliomas of all grades. J Neurooncol 2009;91:19-26.
46. Gregory SG, Barlow KF, McLay KE, et al. The DNA sequence and biological annotation of human chromosome 1. Nature 2006;441:315-321. (Pubitemid 44050191)